Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06222268 · ClinicalTrials.gov registry record · Phase 1
Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery
A Phase 1 study, sponsored by Wayne State University.
- Not yet
- Registry status
- Phase 1
- Development phase
- 280
- Enrollment target
NCT06222268: Clinical Trial Phase 1 study, sponsored by Wayne State University.
NCT06222268 is a Phase 1 study that has not yet begun recruiting, run by Wayne State University. The registered enrollment target is 280 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (367% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06222268, a Phase 1 study, has not yet begun recruiting, sponsored by Wayne State University.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 280 participants
- Enrollment target
Study Summary
The overall strategy is to recruit veterans with PTSD who report minimal current cannabis use but are interested in or considering therapeutic cannabis to manage mental health symptoms (anxiety, depression, PTSD and/or suicidality). The information gained from this study could lead to the development of new treatments for persons who suffer from post-traumatic stress disorder and maintain better mental health.
Primary Outcome
Clinician Administered PTSD Scale for DSM-5 (CAPS-5 Score), anxiety, mood, suicidality, disability. The CAPS-5 is a clinician interview that determines the presence and severity of PTSD consistent with the Diagnostic \& Statistical Manual 5 (DSM-5) and allows for assessing changes in symptom severity over time. PTSD diagnosis is based on meeting the DSM-5 symptom cluster criteria (minimum threshold of symptoms with a score ≥ 2) with a qualifying criterion A index trauma. The CAPS-5 Total Severi
Interventions
- DRUG Placebo only
- DRUG Cannabidiol (CBD) only
- DRUG Delta-9-tetrahydrocannabinol (THC) only
- DRUG THC:CBD 1:1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2026-03 |
| Est. Completion | 2031-09 |
| Phase | Phase 1 |
What is known before NCT06222268 opens enrollment
NCT06222268 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (367% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo only is the first listed.
NCT06222268 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06222268 about?
NCT06222268 is a clinical study titled "Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery". The overall strategy is to recruit veterans with PTSD who report minimal current cannabis use but are interested in or considering therapeutic cannabis to manage mental health symptoms (anxiety, depression, PTSD and/or suicidality). The information gained from this study could lead to the developmen...
What is the current status of trial NCT06222268?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 280 participants. The study started on 2026-03. Estimated completion is 2031-09.
What interventions are being tested in trial NCT06222268?
The interventions under investigation include: Placebo only (DRUG), Cannabidiol (CBD) only (DRUG), Delta-9-tetrahydrocannabinol (THC) only (DRUG), THC:CBD 1:1 (DRUG).
Who is sponsoring clinical trial NCT06222268?
This trial is sponsored by Wayne State University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06222268's enrollment target sits among peer trials
280 141st of 2000 higher than 1,855 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia